2Bateman ED,Feldman C,O'Brien J.Guideline for the management of chronic obstructive pulmonary disease (COPD):2004 revision[J].S Afr Med J,2004,94(7):559-575.
3Tonnesen P,Carrozzi L,Fagerstrom KO.Smoking cessation in patients with respiratory diseases:a high priority,integral component of therapy[J].Eur Respir J,2007,29(2):390-417.
4Frishman WH.Smoking cessation pharmacotherapy-nicotine and non-nicotine preparations[J].Prev Cardiol,2007,10(2):10-22.
5Anzueto A.Clinical course of chronic obstructive pulmonary disease:review of therapeutic interventions[J].Am J Med,2006,119(10):46-53.
7Kardos P,Wencker M,Glaab T.Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2007,175(2):144-149.
8Dekhuijzen PN.Acetylcysteine in the treatment of severe COPD[J].Ned Tijdschr Geneeskd,2006,150(22):1222-1226.
9Rahman I,Adcock IM.Oxidative stress and redox regulation of lung inflammation in COPD[J].Eur Respir J,2006,28(1):219-242.
10Van Driel MF.Phosphodiesterase inhibitors:effectiveness and new applications[J].Ned Tijdschr Geneeskd,2006,150(29):1613-1616.
2GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
3Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
4Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
